Akrotome Imaging, INC
Charlotte, NC · Medtech · Private
Intraoperative topical fluorescent molecular probe for real-time breast cancer margin detection during surgery
- Grants
- $7.5M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $250K
- 1 award · Health and Human S
- #437 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2011201320152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Health and Human Services · TAS::75 0849::TAS SBIR Topic 307 Phase I Novel Imaging Agents To Expand The Clinical Toolkit For Cancer Diagnosis, Staging, And | $249,912 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Intraoperative assessment of non-melanoma skin cancer margins using NIRF probes. | $792,080 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Intraoperative assessment of non-melanoma skin cancer margins using NIRF probes. | $1,669,473 | |
| Federal grant | Department of Health and Human Services · Phase II · Intraoperative assessment of non-melanoma skin cancer margins using NIRF probes. | $877,393 | |
| Federal grant | Department of Health and Human Services · Phase I · An clinical imaging platform for the intraoperative assessment of marginal tissue after BCS resection using in-vivo topical application of a cathepsin-targeted molecular probe | $281,748 | |
| Federal grant | Department of Health and Human Services · Phase I · An clinical imaging platform for the intraoperative assessment of marginal tissue after BCS resection using in-vivo topical application of a cathepsin-targeted molecular probe | $281,748 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Along the continuum for an IND: An In-Vivo large animal study for opticalimage guided surgery of spontaneous breast cancer. | $995,636 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Along the continuum for an IND: An In-Vivo large animal study for opticalimage guided surgery of spontaneous breast cancer. | $1,796,851 | |
| Federal grant | Department of Health and Human Services · Phase II · Along the continuum for an IND: An In-Vivo large animal study for opticalimage guided surgery of spontaneous breast cancer. | $801,215 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 434 | HYDROCISION INC | $252K | $6.2M |
| 435 | Terapio Corp | $250K | $574K |
| 436 | TYMPANOGEN, INC. | $250K | $2.2M |
| 437 | Akrotome Imaging, INC | $250K | — |
| 438 | Specific Diagnostics, Inc. | $249K | $17M |
| 439 | Otolith Sound Inc | $248K | $31M |
| 440 | INSTADIAGNOSTICS INC | $244K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.